Loading...
•
Jun 30, 2021
Keros Q2 2021 Earnings Report
Keros Therapeutics reported a net loss due to increased research and development efforts and additional infrastructure expenses.
Key Takeaways
Keros Therapeutics reported a net loss of $15.6 million for the second quarter of 2021, driven by increased research and development expenses and additional infrastructure costs. The company's cash and cash equivalents were $237.1 million as of June 30, 2021, expected to fund operations into the fourth quarter of 2023.
Announced preliminary results from Phase 2 clinical trial of KER-050.
Executive leadership changes with Simon Cooper appointed as Chief Medical Officer.
Issued a foundational U.S. patent for novel therapeutic proteins, including KER-050.
Initiated dosing for Cohort 3 of the Phase 2 clinical trial evaluating KER-050 in patients with myelodysplastic syndromes.
Forward Guidance
Keros expects that the cash and cash equivalents it had on hand at June 30, 2021 will fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...